Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.4B | ¥7.9B | −81.6% |
| Operating Income | −¥5.4B | ¥0.9B | −700.0% |
| Ordinary Income | −¥5.2B | ¥1.2B | −525.4% |
| Net Income | −¥5.2B | ¥0.8B | −719.0% |
| ROE | −47.1% | 5.3% | - |
Executive Summary
FY2026 Q3 results show severe deterioration with revenue of 1.4 billion yen (YoY -81.6%), operating loss of -5.4 billion yen (prior year profit of 0.9 billion yen, YoY -700.0%), ordinary loss of -5.2 billion yen (prior year profit of 1.2 billion yen, YoY -525.4%), and net loss of -5.2 billion yen (prior year profit of 0.8 billion yen, YoY -719.0%). The company maintained a gross margin of 90.8% at 1.3 billion yen, but SG&A expenses of 6.7 billion yen significantly exceeded revenue, driving the operating loss. Non-operating income of 0.2 billion yen including FX gains of 0.3 billion yen partially offset losses, resulting in ordinary loss of -5.2 billion yen. Basic EPS deteriorated to -20.20 yen from 3.30 yen YoY. Despite these losses, balance sheet liquidity remains strong with cash and deposits of 11.8 billion yen representing 70.7% of total assets of 16.7 billion yen, and equity ratio of 66.1%, though retained earnings declined to -5.7 billion yen from -0.5 billion yen prior year.
Performance Drivers
Revenue collapsed by 81.6% from 7.9 billion yen to 1.4 billion yen, indicating a fundamental shift in business structure or timing of sales recognition. The company maintained a high gross margin of 90.8% with cost of sales of only 0.1 billion yen, suggesting the core product economics remain intact. However, SG&A expenses of 6.7 billion yen overwhelmed the 1.3 billion yen gross profit, representing 463.6% of revenue and creating an operating loss of -5.4 billion yen versus prior year operating profit of 0.9 billion yen. The dramatic increase in SG&A burden relative to revenue indicates fixed cost structure unable to flex with revenue decline. Non-operating items contributed positively with 0.2 billion yen net gain, primarily from FX gains of 0.3 billion yen and interest income of 0.0 billion yen. Ordinary loss reached -5.2 billion yen versus prior year ordinary profit of 1.2 billion yen, representing a swing of 6.4 billion yen. Tax expense was minimal at 0.0 billion yen given the loss position, resulting in net loss of -5.2 billion yen. The gap between operating loss (-5.4 billion yen) and ordinary loss (-5.2 billion yen) of approximately 0.2 billion yen reflects the modest cushion from non-operating income. This represents a revenue down/profit down pattern, with the profitability deterioration significantly outpacing the revenue decline due to operating leverage and fixed cost rigidity.
Key Metrics
[Profitability] ROE of -47.1% reflects severe earnings deterioration, compared to the pharma industry median of -35.8% in 2025-Q3, indicating performance below industry peers. Operating margin of -372.4% significantly underperforms the industry median of -218.2%, representing one of the lowest margins in the sector. Net profit margin of -358.6% also trails the industry median of -216.8%. Asset turnover of 0.087 times falls below the industry median of 0.17, indicating weak asset utilization efficiency. Financial leverage of 1.51 times aligns closely with the industry median of 1.47. [Cash Quality] Cash and deposits of 11.8 billion yen provide coverage of 2.31 times current liabilities of 5.1 billion yen, with current ratio of 316.7% substantially exceeding the industry median of 6.62 times when expressed consistently. [Investment Efficiency] Total asset turnover of 0.087 indicates low revenue generation per asset base. Receivables turnover days increased significantly as trade receivables declined from 5.5 billion yen to 0.1 billion yen, moving faster than the industry median of 151.55 days. [Financial Health] Equity ratio of 66.1% slightly trails the industry median of 67.8% but remains healthy. Current ratio of 316.7% demonstrates strong short-term liquidity. Debt-to-equity ratio of 4.5% indicates conservative leverage with long-term loans of 0.5 billion yen representing minimal financial risk.
Cash Flow Analysis
Cash and deposits increased from prior period levels to 11.8 billion yen, representing 70.7% of total assets and providing substantial liquidity buffer despite operating losses. The balance sheet shows significant working capital efficiency changes, with trade receivables declining 97.9% from 5.5 billion yen to 0.1 billion yen, and trade payables declining 96.9% from 1.4 billion yen to 0.0 billion yen, suggesting fundamental changes in sales and procurement cycles coinciding with the revenue collapse. Inventories remained relatively stable at 0.1 billion yen. Current assets of 16.3 billion yen consist predominantly of cash, indicating liquidity is not locked in operating assets. The operating loss position implies cash consumption from operations, though the strong cash balance of 11.8 billion yen provides coverage of 2.31 times short-term debt and current liabilities of 5.1 billion yen combined. Long-term loans remained modest at 0.5 billion yen. The dramatic reduction in receivables and payables suggests either business model transition or timing effects around quarter-end. Retained earnings declined 5.2 billion yen to -5.7 billion yen, directly reflecting the net loss and indicating equity erosion that will require monitoring if losses continue.
Earnings Quality
Ordinary loss of -5.2 billion yen versus operating loss of -5.4 billion yen shows net non-operating contribution of approximately 0.2 billion yen, representing 14% of revenue. Non-operating income comprises primarily FX gains of 0.3 billion yen and interest income of 0.0 billion yen, partially offset by minimal non-operating expenses of 0.0 billion yen. The FX gains appear as a one-time favorable item and should not be considered recurring. Non-operating income of 0.2 billion yen represents 14% of revenue, indicating moderate reliance on non-core items relative to the operating loss. The gross margin of 90.8% suggests healthy underlying product economics, but the SG&A burden of 463.6% of revenue overwhelms this, pointing to a structural cost issue rather than product margin deterioration. Extraordinary losses were minimal at 0.0 billion yen with no significant asset disposals or impairments recorded. The quality of earnings is weak given the operating loss position, though the high cash balance suggests near-term financial stability is maintained. Without operating cash flow disclosure, the cash generation quality cannot be directly assessed, though the negative net income and reduction in working capital assets implies cash consumption from operations during the period.
Guidance Update
Full-year guidance projects revenue of 2.0 billion yen (YoY -85.3%), operating loss of -7.6 billion yen, ordinary loss of -7.4 billion yen, and net loss of -7.4 billion yen with EPS forecast of -28.68 yen. Q3 cumulative progress rates cannot be calculated from single quarter data, but Q3 revenue of 1.4 billion yen represents 70% of the full-year forecast of 2.0 billion yen, suggesting Q4 revenue is expected at only 0.6 billion yen. Q3 operating loss of -5.4 billion yen represents 71% of the full-year operating loss forecast of -7.6 billion yen, implying Q4 operating loss of approximately -2.2 billion yen. The guidance indicates the company expects continued losses through year-end but at a moderating rate in Q4. The revenue forecast of 2.0 billion yen for the full year down 85.3% YoY suggests a fundamental business transition or restructuring is underway. The dividend forecast of 0.00 yen confirms no shareholder distribution during this loss period. No guidance revision was disclosed this quarter, indicating the company is tracking to its previously announced expectations for significant contraction and losses.
Risk Factors
Revenue concentration risk with 81.6% YoY decline indicating heavy dependence on limited sales channels or customers, with potential disruption in core business model requiring urgent diversification or recovery measures. Operating leverage risk as SG&A expenses of 6.7 billion yen far exceed revenue of 1.4 billion yen (463.6% ratio), creating cash burn that will deplete the 11.8 billion yen cash reserve if sustained, requiring immediate cost restructuring. Equity erosion risk with retained earnings declining to -5.7 billion yen and continued losses forecast, potentially requiring capital injection or debt financing if turnaround is delayed, though current equity ratio of 66.1% provides buffer.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis) The company's performance metrics substantially underperform pharma industry benchmarks across profitability and efficiency dimensions. Profitability indicators including ROE of -47.1% (Industry Median -35.8%), Operating Margin of -372.4% (Industry Median -218.2%), and Net Profit Margin of -358.6% (Industry Median -216.8%) all rank in the bottom quartile, indicating severe operational challenges relative to peers. Efficiency metrics show Asset Turnover of 0.087 times versus Industry Median of 0.17, placing the company below median in capital productivity. Financial Health metrics are relatively stronger, with Equity Ratio of 66.1% close to the Industry Median of 67.8%, and Current Ratio of 316.7% significantly exceeding the industry norm, indicating the company maintains superior liquidity despite earnings weakness. Financial Leverage of 1.51 times aligns with Industry Median of 1.47, showing balanced capital structure. The company's Revenue Growth YoY of -81.6% dramatically underperforms the Industry Median decline of -12.5%, suggesting company-specific challenges beyond sector headwinds. (Industry: Pharmaceutical, Comparison: 2025-Q3, Source: Proprietary analysis of 13 companies)
Key Takeaways from Earnings
Structural revenue collapse of 81.6% YoY to 1.4 billion yen represents the most critical issue, requiring confirmation of whether this reflects temporary sales timing, customer concentration loss, or permanent business model shift, with Q4 recovery trajectory being the key monitoring point. Despite severe losses, balance sheet resilience remains notable with cash and deposits of 11.8 billion yen providing 2.31 times coverage of current liabilities, offering runway for restructuring, though the 6.7 billion yen annual SG&A run rate implies less than two years of cash runway at current burn rate absent revenue recovery. The 90.8% gross margin preservation indicates core product value proposition remains intact, suggesting the path to recovery centers on revenue restoration and SG&A rationalization rather than fundamental product economics, making cost reduction execution and sales pipeline visibility the two critical factors for turnaround assessment.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was severely weak, with a sharp revenue contraction converting the prior-year profit into a substantial loss. Revenue fell 81.6% year on year to ¥145 million. Operating loss was ¥540 million, compared with operating profit of ¥90 million in the prior-year period. Net loss was ¥520 million, versus net income of ¥84 million a year earlier. Gross profit declined to ¥132 million from ¥728 million, largely tracking the revenue decline. The gross margin nevertheless remained high at 90.8%, down only approximately 116 basis points from 92.0% in the prior-year period. This indicates that the deterioration was principally a scale and fixed-cost absorption issue rather than a material deterioration in unit-level gross profitability. SG&A expenses declined only 5.6% year on year to ¥672 million, far slower than the 81.6% revenue decline. Consequently, the operating margin collapsed to -372.4% from approximately 11.4%, a deterioration of roughly 3,838 basis points. Ordinary loss was ¥519 million, with non-operating income of ¥22 million, including subsidy income of ¥18 million, providing only limited offset to the operating loss. Net margin was -358.6%, compared with about 10.6% in the prior-year period. Annualized ROE was -62.8%, reflecting the exceptionally negative profit margin rather than elevated financial leverage. Cash and deposits remained substantial at ¥1.18 billion, equivalent to 70.7% of total assets, and the current ratio was a strong 316.7%. Management's full-year forecast calls for revenue of ¥200 million and net loss of ¥740 million; Q3 revenue has reached 72.5% of the full-year target, slightly below the standard 75% seasonal progress rate. Q3 operating loss has reached 71.1% of the full-year projected loss, implying a smaller ¥220 million operating loss in Q4 if the forecast is achieved. The central near-term issue is whether revenue generation can recover sufficiently to absorb the existing SG&A base, while preserving the company’s sizeable liquidity buffer.
Profitability Analysis
The annualized DuPont ROE decomposition is net profit margin of -358.6% × asset turnover of 0.116x × financial leverage of 1.51x, producing annualized ROE of -62.8%. The dominant driver of the negative ROE is the net profit margin, not asset turnover or leverage. Revenue fell to ¥145 million while the gross margin remained 90.8%, demonstrating that the core profitability issue is insufficient revenue volume relative to operating expenses. SG&A expense of ¥672 million was 4.64 times revenue, compared with approximately 80.5% of revenue in the prior-year period. SG&A decreased by roughly ¥34 million year on year, whereas revenue decreased by roughly ¥647 million, demonstrating pronounced negative operating leverage. Operating margin therefore moved from approximately 11.4% to -372.4%. The reported interest burden of 0.961 indicates that interest expense had a limited incremental effect on the loss relative to the operating loss. The tax burden of 1.002 reflects a minimal tax charge despite pre-tax losses and does not provide a meaningful profitability offset. The high gross-margin model can create strong earnings leverage if revenue recovers, but the current cost base makes reported profitability highly sensitive to sales, licensing, or milestone timing. The annualized asset turnover of 0.116x is low, consistent with a cash-rich balance sheet supporting a currently small revenue base. The 98.0% work-in-process share of inventory identified in the quality alerts indicates that inventory is concentrated in unfinished projects, which is consistent with a development-oriented operating model but raises execution and conversion risk. The quality alert for EBIT margin of -372.4% is therefore rooted in the exceptional mismatch between revenue and the SG&A structure; its impact is that a sustained revenue shortfall would continue to erode equity despite the healthy gross margin.
Growth Assessment
Revenue declined 81.6% year on year to ¥145 million, following prior-year revenue of ¥792 million, and the scale of this decrease is the key determinant of the earnings reversal. The FY2026 full-year revenue forecast is ¥200 million, implying Q4 revenue of ¥55 million. Q3 progress against the revenue forecast is 72.5%, 2.5 percentage points below the standard 75% Q3 pace. The forecast implies a full-year revenue decline of 85.3% year on year, indicating that management does not currently anticipate a broad-based rebound before fiscal year-end. Operating loss of ¥540 million represents 71.1% of the projected full-year operating loss of ¥760 million. Net loss of ¥520 million represents 70.3% of the projected full-year net loss of ¥740 million. On an implied Q4 basis, the forecast assumes operating loss and net loss of approximately ¥220 million each, which would be an improvement from the cumulative Q3 loss run-rate but would still leave the business materially unprofitable. Gross margin resilience at 90.8% supports the potential for operating leverage if revenue normalizes. However, the gap between revenue and SG&A is currently too large for the gross margin to translate into earnings. Subsidy income of ¥18 million represented a significant part of ¥22 million non-operating income, so it should not be viewed as a substitute for operating revenue recovery. Revenue sustainability should be assessed primarily through the company’s ability to convert work in process and contract liabilities into recognized sales while controlling the SG&A base.
Financial Health
Liquidity is strong on reported balance-sheet measures, with current assets of ¥1.63 billion against current liabilities of ¥515 million, resulting in a current ratio of 316.7% and quick ratio of 315.6%. Working capital was ¥1.12 billion. Cash and deposits totaled ¥1.18 billion and represented 70.7% of total assets, providing a meaningful buffer against the current operating loss. Total equity was ¥1.11 billion, or 66.1% of total assets, while total liabilities were ¥567 million. Debt-to-capital was low at 4.5%, based on reported covenant metrics. Disclosed long-term loans were ¥53 million, while the balance-sheet detail also identifies a ¥22 million current portion of long-term loans; cash substantially exceeds these disclosed borrowings. Accordingly, there is no apparent short-term debt maturity mismatch: current assets exceed current liabilities by more than three times. The reported D/E ratio is 0.51x, below the 2.0x threshold that would indicate aggressive debt financing. The interest-coverage quality alert of -1,063.0x is a mechanical consequence of negative EBIT of ¥540 million against interest expense of ¥5 million, rather than a high nominal interest burden. Its root cause is the operating loss, not excessive leverage; nevertheless, its impact is that debt-service capacity cannot be supported by current operating earnings. Accounts receivable declined ¥535 million year on year to ¥11 million, and accounts payable declined ¥131 million to ¥4 million. Contract liabilities declined ¥65 million to ¥251 million. These movements indicate a substantially smaller operating working-capital footprint than in the prior-year period, though the decline in contract liabilities also reduces a source of advance funding. Retained earnings deteriorated from negative ¥47 million to negative ¥567 million, reflecting the current-period loss and reducing the equity cushion. PPE declined 27.6% to ¥32 million, but fixed assets remain only 1.9% of total assets and do not represent a material balance-sheet concentration.
Notable B/S Changes
Cash and deposits: -¥556 million (-36.2%) to ¥1.18 billion - cash remains substantial but has declined materially alongside the loss-making period. Total assets: -¥831 million (-33.2%) to ¥1.67 billion - balance-sheet scale contracted significantly year on year. Retained earnings: -¥520 million to negative ¥567 million - cumulative losses have materially reduced the retained earnings position and equity cushion. Accounts receivable: -¥535 million (-97.9%) to ¥11 million - operating receivables contracted sharply, consistent with the lower revenue base and/or collection of prior balances. Accounts payable: -¥131 million (-96.9%) to ¥4 million - lower trade payables reduce short-term supplier financing and accompany the smaller operating activity base. Contract liabilities: -¥65 million (-20.6%) to ¥251 million - the remaining balance is material, but the decline reduces advance-funding support relative to the prior period. PPE: -¥12 million (-27.6%) to ¥32 million - fixed assets are modest relative to total assets, limiting the direct balance-sheet impact of this decline.
Cash Flow Quality
The available balance-sheet movements indicate a sharp contraction in operating working capital: accounts receivable decreased by ¥535 million and accounts payable decreased by ¥131 million year on year. Cash and deposits decreased by ¥556 million year on year to ¥1.18 billion despite the lower receivables balance, indicating that the reduction in receivables has not prevented a material decline in the cash balance. Quality alerts identify inventory days of 5,692 days and 111 days, respectively, as well as a cash conversion cycle of 5,631 days. The root cause of these alerts is the combination of very low reported revenue and inventory tied predominantly to work in process. The 5,692-day measure is particularly sensitive to the current low-revenue base, while the 111-day alert still exceeds the stated 60-day threshold. The high work-in-process ratio alert is rooted in work in process of ¥286 million, identified as 98.0% of inventory in the quality metrics. In a development-oriented business, a high work-in-process mix may be structurally more common than in a conventional finished-goods manufacturer, but it increases the risk that cash is tied up in projects with delayed commercialization or revenue recognition. The impact is reduced working-capital flexibility and greater dependence on successful conversion of development activity into sales. The long cash-conversion-cycle alert should therefore be monitored as an execution and liquidity-management risk despite the current cash balance. The cash reserve is sufficient to support near-term operations, but the continuation of large operating losses would reduce that buffer over time.
Dividend Sustainability
The Q2 dividend per share was ¥0, and the full-year forecast also indicates DPS of ¥0. Accordingly, there is no current cash dividend commitment requiring coverage by earnings or cash resources. With cumulative net loss of ¥520 million and a full-year net loss forecast of ¥740 million, retaining liquidity is financially prudent. The absence of a dividend avoids an incremental capital-allocation burden while the company seeks to stabilize revenue and reduce losses. Dividend policy outlook is likely to remain dependent on a sustained restoration of operating profitability and preservation of the cash balance.
Risk Assessment
Business risks include Revenue concentration and timing risk: revenue fell 81.6% year on year to ¥145 million, making earnings highly dependent on the timing and conversion of commercial, development, licensing, or project-related activity., Negative operating leverage: SG&A declined only 5.6% while revenue declined 81.6%, producing an operating margin of -372.4%. A prolonged low-revenue environment would sustain substantial losses., Development and commercialization risk: work in process of ¥286 million and the 98.0% WIP ratio alert indicate that a large share of inventory-related activity depends on successful completion and monetization., Pharmaceutical industry risk: product development, commercialization, approval, intellectual-property, and partner-execution outcomes can be uncertain and may delay or reduce anticipated revenue generation., Working-capital conversion risk: quality alerts for inventory days of 5,692 days and 111 days, and a cash conversion cycle of 5,631 days, indicate slow inventory conversion relative to current sales..
Financial risks include Earnings-based debt-service risk: interest coverage of -1,063.0x is below the 2.0x warning threshold because EBIT is negative. While nominal borrowings are low, recurring losses leave no operating earnings coverage for interest., Cash-burn risk: cash and deposits declined ¥556 million year on year to ¥1.18 billion while the company reported a ¥520 million cumulative net loss., Equity erosion risk: retained earnings worsened to negative ¥567 million and total equity fell ¥482 million year on year to ¥1.11 billion., Advance-funding risk: contract liabilities declined ¥65 million to ¥251 million, which may reduce the balance of customer or partner advances supporting operations..
Key concerns include Highest priority: restoring revenue scale, because the gross margin remains strong but is currently insufficient to absorb ¥672 million of cumulative SG&A., High priority: monitoring cash balance and quarterly loss progression against the implied Q4 operating loss of ¥220 million., High priority: validating conversion of work in process into revenue, given the high-WIP-ratio and extended cash-conversion-cycle alerts., Moderate priority: maintaining funding discipline, as operating losses rather than leverage are the source of the debt-service warning., The principal risk metrics should be interpreted in the context of an exceptionally low revenue base, which can amplify inventory-day, cash-conversion-cycle, margin, and coverage ratios..
Investment Implications
Key takeaways include The earnings reversal is overwhelmingly attributable to the 81.6% revenue decline and negative operating leverage, rather than gross-margin deterioration., Gross margin remained high at 90.8%, preserving upside operating leverage if revenue generation recovers., Liquidity remains a relative strength, with ¥1.18 billion in cash, a 316.7% current ratio, and debt-to-capital of 4.5%., The full-year forecast implies continued losses but a smaller Q4 loss than the cumulative Q3 run-rate., High work-in-process concentration and prolonged inventory/cash-conversion metrics make execution and monetization progress central to the financial outlook..
Metrics to watch include Quarterly revenue progression relative to the ¥200 million full-year forecast, SG&A expense trajectory relative to revenue recovery, Operating loss progression versus the ¥760 million full-year forecast, Cash and deposits and the rate of equity reduction, Contract liabilities, accounts receivable, work in process, and inventory-conversion metrics, Interest coverage as operating profitability improves or deteriorates.
Regarding relative positioning, The company combines an asset-light, high-gross-margin profile with a currently very low revenue base and substantial operating losses. Its liquidity and low debt-to-capital distinguish its balance-sheet position from a highly leveraged loss-making issuer, but its current profitability and operating efficiency are materially below normal corporate and pharmaceutical-sector benchmarks.